Cite
HARVARD Citation
Vogl, D. et al. (2017). Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Leukemia & lymphoma. 58 (8), pp. 1872-1879. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Vogl, D. et al. (2017). Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Leukemia & lymphoma. 58 (8), pp. 1872-1879. [Online].